Mark Davies
Founder
Hooke Bio Ltd.
Hooke Bio develops the patent-protected Mera system, a high-throughput screening platform for analyzing 3D microtissues such as spheroids and organoids. This technology aims to reduce reliance on animal models in preclinical drug development by providing biological data that accelerates the drug discovery process.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$2.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Preclinical drug development heavily relies on animal models, which are expensive, time-consuming, and often poorly predictive of human response. Traditional in vitro cell culture lacks the complex 3D microenvironment necessary to accurately mimic in vivo conditions.
Solution
Hooke Bio's Mera system is a high-throughput screening platform designed for analyzing 3D microtissues, including spheroids, organoids, and tumouroids. The system generates biological data from microtissues to reduce the reliance on animal models in preclinical studies. By providing a more physiologically relevant environment, the Mera system aims to accelerate the drug discovery process and improve the translatability of preclinical findings.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies involved in preclinical drug development.
Features
- High-throughput screening of 3D microtissues
- Fully integrated system for generating biological data
- Patent-protected technology
- Bioconsumable plate